Immuneering grants CFO 650,000 stock options
Immuneering Corp granted Chief Financial Officer Andrew Gengos stock options covering 650,000 shares of Class A Common Stock at an exercise price of $4.78 per share, expiring July 16, 2036.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Immuneering Corp granted Chief Financial Officer Andrew Gengos stock options covering 650,000 shares of Class A Common Stock at an exercise price of $4.78 per share, expiring July 16, 2036. The options vest monthly over four years under a detailed, step-up vesting schedule tied to continued employment.
Insider Trade Summary
Grant/Award: 650,000 shares
Grant/Award
1 txn
Insider
Gengos Andrew
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option F1 | 650,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option — 650,000 contracts (Direct)
Footnotes (1)
- F1. Subject to the reporting person's continued employment through each applicable vesting date, 8.33333% of the shares underlying the stock option shall vest on each of the first, second and third monthly anniversary of the grant transaction date (the "Grant Date"); 1.6667% of the shares underlying the stock option shall vest on the fourth monthly anniversary of the Grant Date and on each monthly anniversary thereafter until the one year anniversary of the Grant Date; 3.33333% of the shares underlying the stock option shall vest on each monthly anniversary following the one-year anniversary of the Grant Date until the second anniversary of the Grant Date; and 0.833333% of the of the shares underlying the stock option shall vest on each monthly anniversary following the second anniversary of the Grant Date until the fourth anniversary of the Grant Date, such that all shares underlying the stock option shall be fully vested on the fourth anniversary of the Grant Date.
Key Figures
Stock options granted: 650,000 shares
Exercise price: $4.78 per share
Expiration date: July 16, 2036
+2 more
5 metrics
Stock options granted
650,000 shares
Stock option grant to CFO Andrew Gengos on 2026-07-16
Exercise price
$4.78 per share
Exercise price of the granted stock options
Expiration date
July 16, 2036
Expiration of CFO stock option grant
Underlying shares
650,000 shares
Class A Common Stock underlying the stock option grant
Post-grant derivative holdings
650,000 options
Total stock options held after the reported grant
Key Terms
Stock Option, exercise price, vesting, Class A Common Stock
4 terms
Stock Option financial
"Stock Option covering 650,000 shares granted to the CFO"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"stock option at an exercise price of $4.78 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares underlying the stock option shall vest on each monthly anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Class A Common Stock financial
"underlying security title listed as Class A Common Stock"
Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Immuneering (IMRX) report for its CFO?
Immuneering granted its CFO, Andrew Gengos, a stock option covering 650,000 shares of Class A Common Stock. The option has a multi-year monthly vesting schedule and provides equity-based compensation rather than an immediate cash transaction.
How many stock options were granted to Immuneering (IMRX) CFO Andrew Gengos?
Andrew Gengos received a stock option for 650,000 shares of Class A Common Stock. All 650,000 shares remain subject to vesting conditions tied to his continued employment and will vest in stages over a four-year period.
What is the exercise price and underlying stock for the IMRX CFO options grant?
The granted stock option allows purchase of Class A Common Stock at an exercise price of $4.78 per share. The option covers 650,000 underlying shares and gives potential future ownership if exercised once the relevant portions have vested.
How do the 650,000 Immuneering (IMRX) stock options for the CFO vest?
The option vests monthly over four years. Early vesting tranches are 8.33333% for each of the first three months, followed by 1.6667%, then 3.33333%, then 0.833333% monthly, so all shares vest by the fourth anniversary of the grant date.
When do the Immuneering (IMRX) CFO stock options expire?
The stock option granted to CFO Andrew Gengos expires on July 16, 2036. After that expiration date, any unexercised portion of the 650,000-share option will lapse and can no longer be used to purchase Class A Common Stock.
Were the Immuneering (IMRX) CFO options granted under a Rule 10b5-1 trading plan?
The report indicates the transaction was not designated as made under a Rule 10b5-1 trading plan. This entry reflects a compensation-related stock option grant rather than pre-arranged open-market buying or selling activity under such a plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates